| Literature DB >> 26330515 |
Pierre Boudry1, Ekaterina Semenova2, Marc Monot3, Kirill A Datsenko4, Anna Lopatina5, Ognjen Sekulovic6, Maicol Ospina-Bedoya6, Louis-Charles Fortier6, Konstantin Severinov7, Bruno Dupuy3, Olga Soutourina8.
Abstract
UNLABELLED: Clostridium difficile is the cause of most frequently occurring nosocomial diarrhea worldwide. As an enteropathogen, C. difficile must be exposed to multiple exogenous genetic elements in bacteriophage-rich gut communities. CRISPR (clustered regularly interspaced short palindromic repeats)-Cas (CRISPR-associated) systems allow bacteria to adapt to foreign genetic invaders. Our recent data revealed active expression and processing of CRISPR RNAs from multiple type I-B CRISPR arrays in C. difficile reference strain 630. Here, we demonstrate active expression of CRISPR arrays in strain R20291, an epidemic C. difficile strain. Through genome sequencing and host range analysis of several new C. difficile phages and plasmid conjugation experiments, we provide evidence of defensive function of the CRISPR-Cas system in both C. difficile strains. We further demonstrate that C. difficile Cas proteins are capable of interference in a heterologous host, Escherichia coli. These data set the stage for mechanistic and physiological analyses of CRISPR-Cas-mediated interactions of important global human pathogen with its genetic parasites. IMPORTANCE: Clostridium difficile is the major cause of nosocomial infections associated with antibiotic therapy worldwide. To survive in bacteriophage-rich gut communities, enteropathogens must develop efficient systems for defense against foreign DNA elements. CRISPR-Cas systems have recently taken center stage among various anti-invader bacterial defense systems. We provide experimental evidence for the function of the C. difficile CRISPR system against plasmid DNA and bacteriophages. These data demonstrate the original features of active C. difficile CRISPR system and bring important insights into the interactions of this major enteropathogen with foreign DNA invaders during its infection cycle.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26330515 PMCID: PMC4556805 DOI: 10.1128/mBio.01112-15
Source DB: PubMed Journal: MBio Impact factor: 7.867
FIG 1 Positions of CRISPR-Cas I-B loci in C. difficile strains 630 and R20291. (A) Schematic view of the genomic locations of expressed CRISPR arrays in strains 630 and R20291. CRISPR arrays (CR) are numbered according to the CRISPRdb database. Arrowheads indicate the array position, and transcriptional orientation is indicated by colors as follows: green for the plus or coding strand and blue for the minus or noncoding strand. The locations of associated cas operons, prophage regions, and replication origin (ori) are indicated. The right and left replichores are shown by black arrowheads. (B) Organization of the operons for the complete (CD2982-CD2975) and partial cas operon (CD2455-CD2451) from C. difficile strain 630 (left) and for the complete (CDR20291_2817-2810) and partial cas operons (CDR20291_2348-2344 and CDR20291_2998-2994) from C. difficile strain R20291 (right). The same color was used for homologous cas genes.
FIG 2 Alignment of CRISPR regions from C. difficile strain 630. The sequences of 10 independent CRISPR arrays (CR) numbered according to the CRISPRdb database were aligned using the CLUSTALW program, and the upstream part of the alignment is shown. The names of the highly expressed arrays are shown in red. The positions of TSS “+1” identified by 5′-end RNA-seq are highlighted in magenta (24). The potential −35 and −10 promoter elements corresponding to sigma A-dependent consensus sequences are indicated by blue and green background, respectively. Direct repeats (DR) are highlighted in yellow and are numbered according to the transcriptional order (DR1, DR2). The sequences of the first spacer (Spacer 1) from each array and a conserved leader motif are indicated by a solid red line and broken black line, respectively. The region used for artificial CRISPR array engineering in the E. coli chromosome is delimited by short black vertical arrows.
FIG 3 C. difficile strain 630 CRISPR repeat consensus sequence in comparison with other CRISPR-Cas I-B systems. (A) The 29-bp direct repeats from all expressed CRISPR arrays of strain 630 were aligned, and a consensus sequence was established on the basis of this alignment using WebLogo (http://weblogo.berkeley.edu). A consensus repeat sequence for subtype I-B CRISPR-Cas systems is shown below the WebLogo sequence and was determined by the method in reference 16 (R means A or G). (B) Predicted RNA secondary structure for repeat sequence of C. difficile strain 630 compared to other repeat sequences for subtype I-B CRISPR-Cas systems (17, 22, 23, 26). The RNA secondary structure was predicted using the Mfold software (66). The proposed position of pre-crRNA cleavage by the Cas6 protein that generates the 8-nt 5′ tag of crRNA during processing is indicated.
FIG 4 Spacer homology analysis of CRISPR arrays for nine C. difficile strains. The spacer content of each CRISPR array is shown. The names of CRISPR arrays transcribed on the plus or minus strand are shown on green and red, respectively. The same number was assigned to identical spacers within CRISPR arrays from different strains. Color was used to show the spacer matching the clostridial phage genome sequence (red), plasmid (dark green), chromosomal prophage region (yellow), other chromosomal region (light green), chromosome and phage or plasmid (taupe), both phage and plasmid (blue), phage and prophage (mauve), and three groups (chromosome, plasmid, and phage0 (gray). Potential spacer deletion events are shown in bold type.
Phage sensitivity of C. difficile strains compared to CRISPR spacer homology to phage protospacers
| Phage | Strain | No. of spacers with exact or allowed match | PAM | Expected phage sensitivity | Experimental phage sensitivity |
|---|---|---|---|---|---|
| phiCD27 | 630 | 8 (6 leader-proximal) | CCT/A | Expected resistant | Resistant |
| R20291 | 2 | CCA/T | Expected resistant | Resistant | |
| phiC2 | 630 | 2 | CCA | Expected resistant | ND |
| 630 | 1 | ||||
| R20291 | 2 | CCA/T | Expected resistant | ND | |
| phiCD38-2 | 630 | 3 | CCA | Expected resistant | Resistant |
| 630 | 1 | ||||
| R20291 | 3 (leader-distal) | CCA | Possibly sensitive | Sensitive ( | |
| phiCD119 | 630 | 1 | Expected sensitive | ND | |
| R20291 | 1 | CCA | Expected resistant | ND | |
| phiCD6356 | 630 | 2 | CCA/T | Expected resistant | ND |
| R20291 | 4 | CCA/T | Expected resistant | ND | |
| phiMMP01 | 630 | 3 | CCA/T | Expected resistant | Resistant |
| R20291 | 1 | CCA | Expected resistant | Resistant ( | |
| phiMMP03 | 630 | 2 | CCA | Expected resistant | Resistant |
| 630 | 1 | ||||
| R20291 | 2 | CCA/T | Expected resistant | Resistant ( | |
| phiCD24-1 | 630 | 0 | Expected sensitive | Resistant | |
| R20291 | 0 | Expected sensitive | Resistant | ||
| phiCD52 | 630 | 0 | Expected sensitive | Resistant | |
| R20291 | 2 | CCA/T | Expected resistant | Resistant ( | |
| phiCD111 | 630 | 3 | CCA | Expected resistant | Resistant |
| 630 | 1 | ||||
| R20291 | 1 | CC | Expected sensitive | Resistant | |
| phiCD146 | 630 | 3 | CCA | Expected resistant | Resistant |
| 630 | 1 | ||||
| R20291 | 2 (leader-distal) | CCA | Possibly sensitive | Sensitive ( | |
| R20291 | 1 | C | |||
| phiCD211 | 630 | 4 | CCT/A | Expected resistant | Resistant |
| R20291 | 1 | Expected sensitive | Resistant | ||
| phiCD481-1 | 630 | 1 | Expected sensitive | Resistant | |
| R20291 | 1 | CC | Expected sensitive | Sensitive ( | |
| phiCD505 | 630 | 5 (4 leader-proximal) | CCA/T | Expected resistant | Resistant |
| R20291 | 3 | CCA/T | Expected resistant | Resistant ( | |
| phiCD506 | 630 | 1 | CCA | Expected resistant | Resistant |
| 630 | 1 | CC | |||
| R20291 | 1 | CC | Expected sensitive | Resistant | |
| phiMMP02 | 630 | 5 (leader-proximal) | CCT/A | Expected resistant | Resistant |
| 630 | 1 | ||||
| R20291 | 2 | CCA | Expected resistant | Resistant ( | |
| R20291 | 1 | ||||
| phiMMP04 | 630 | 0 | Expected sensitive | Resistant | |
| R20291 | 1 | CC | Expected sensitive | Resistant | |
| phiCDMH1 | 630 | 2 | CCA | Expected resistant | ND |
| 630 | 1 | C | |||
| R20291 | 1 | CCA | Expected resistant | ND |
For an allowed match between the CRISPR spacer and phage protospacer, we accepted up to five mismatches outside the potential “seed” region (first 8 nt of protospacer except for position 6).
The consensus PAM motif is CCA or CCT. Mismatches in this motif are shown in bold type.
Phage sensitivity was examined by a phage infection spot assay (29). ND, not determined.
Discrepancies between expected and observed resistance probably due to the existence of other resistance mechanisms. The complete genome sequences of Siphoviridae phages phiCD24-1, phiCD111, and phiCD146 and Myoviridae phages phiCD481-1, phiCD505, phiCD506, phiMMP01, phiMMP03, and phiCD52 were deposited in European Nucleotide Archive under accession no. LN681534, LN681535, LN681536, LN681538, LN681539, LN681540, LN681541, LN681542, and PRJEB7856, respectively. The complete genome sequence of phiCD211 was deposited in European Nucleotide Archive under accession no. LN681537.
FIG 5 CRISPR spacer targeting of C. difficile phages. The CRISPR spacer hits are indicated by red flag symbols on the genomes of representative members of clostridial phage groups: myophages phiMMP02 (for phiMMP02/phiCD505 group), phiCD27, phiCDHM1, phiMMP03 (for phiMMP01/phiMMP03 group), phiC2, phiCD119, phiCD481-1 (for phiMMP04/phiCD481-1/phiCD506 group), phiCD211, and siphophages phiCD38-2 (for phiCD38-2/phiCD111/phiCD146 group) and phiCD6356. Late phage genes (blue), early middle genes (pink), and integrase/resolvase genes (yellow) are indicated. One flag symbol corresponds to either a single hit or multiple hits.
FIG 6 PAM identification for CRISPR system in C. difficile. (A) The alignment of regions flanking protospacers targeted by the CRISPR system was used to create the sequence logo by WebLogo for CRISPR spacers from strains 630 and R20291. The 5′ PAM (protospacer adjacent motif) at positions −3, −2, and −1 relative to the first position of the protospacer is indicated. The PAM 3-nucleotide WebLogo created on the basis of potential protospacer flanking regions from nine C. difficile strains is shown below. (B) Efficiency of conjugation of pMTL84121-derived plasmids (carrying p15a Gram-negative bacterial replicon and pCD6 Gram-positive bacterial replicon) and pRPF185-derived plasmids (carrying ColE1 Gram-negative bacterial replicon and pCD6 Gram-positive bacterial replicon). Protospacer 1 CRISPR 16 mutation indicates a G-to-A substitution at the first position. The representative results of three independent experiments are shown.
FIG 7 Functionality of C. difficile cas genes for plasmid interference in E. coli. The transformation efficiency was estimated with pT7Blue derivative plasmids carrying the wild-type (wt) protospacer corresponding to the first spacer of the CRISPR 16 array (CR16) (rows 2 and 5) or a mutated protospacer CR16 (rows 3 and 6) compared to the pT7Blue empty vector used as a negative control (rows 1 and 4). The protospacer plasmid used is indicated to the left of the photographs together with schematic representation of E. coli strains carrying engineered CRISPR arrays with the corresponding spacer under the control of T7 RNAP promoter (T7). E. coli KD623 strain (rows 1 to 3) carries C. difficile CRISPR “miniarray” with the first spacer of CRISPR 16 array flanked by repeats, and E. coli KD626 strain (rows 4 to 6) carries reduced “miniarray” with one repeat lacking spacer sequence. The CRISPR “leader” region (LDR) is indicated. Both strains were transformed with pCDF1-b vector derivative, allowing the expression of C. difficile cas gene set lacking cas1 and cas2 (from CD2982 to CD2977). The Cas protein production and crRNA expression were induced by the addition of 1 mM l-arabinose and 1 mM IPTG. The serial dilutions of transformation mixtures deposited on LB plates with ampicillin are indicated (ND, not diluted).